EKSO BIONICS (EKSO)
NASDAQ:EKSO
Want to see EKSO full AI Analyst Report?
Top Page
EKSO BIONICS
(NASDAQ:EKSO)
Select Model
Select Model
Rating:47Neutral
Price Target:
$11.00
▲(8.37% Upside)
Action:ReiteratedDate:04/29/26
The score is held down primarily by weak financial performance (large losses, cash burn, shrinking equity) and a highly dilutive, control-shifting corporate event. Technicals are a relative positive with an uptrend and moderate momentum, but valuation is constrained by negative earnings and no dividend support.
Positive Factors
Gross margin / product economics
Sustained ~50–60% gross margins indicate strong unit economics for exoskeleton products. Durable product-level margins mean revenue growth can flow through to profits as scale rises, reducing reliance on pricing moves and supporting long-term margin sustainability if fixed costs are controlled.
Negative Factors
Cash burn and weak cash generation
Sustained negative operating cash flow (~-$12M TTM) and negative free cash flow indicate the company is consuming capital to operate. Continued cash burn forces reliance on external financing, limits reinvestment capacity, and heightens dilution risk absent a credible path to positive operating cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin / product economics
Sustained ~50–60% gross margins indicate strong unit economics for exoskeleton products. Durable product-level margins mean revenue growth can flow through to profits as scale rises, reducing reliance on pricing moves and supporting long-term margin sustainability if fixed costs are controlled.
Read all positive factors
EKSO BIONICS (EKSO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.80M
Dividend YieldN/A
Average Volume (3M)56.84K
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth-34.08%
EPS Growth26.18%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-2.04
Shares Outstanding3,563,381
10 Day Avg. Volume46,910
30 Day Avg. Volume56,843
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.32
Price to Sales (P/S)1.64
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit4.91
Enterprise Value/Ebitda-2.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$19.38M
EKSO BIONICS Business Overview & Revenue Model
Company Description
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoH...
How the Company Makes Money
Ekso Bionics makes money primarily by selling and supporting its exoskeleton devices and related offerings to healthcare providers and other institutional customers. Key revenue streams generally include: (1) Product revenue from the sale of exosk...
EKSO BIONICS Key Performance Indicators (KPIs)
EKSO BIONICS Earnings Call Summary
Earnings Call Date:Jul 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 03, 2026
Earnings Call Sentiment Negative
The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.Positive Updates
Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.
Negative Updates
Significant Revenue Decline
Second quarter 2025 revenue of $2.1 million was significantly lower compared to $5 million in the second quarter of 2024, due to delays in Enterprise Health sales.
Read all updates
Q2-2025 Updates
Positive
Negative
Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.
Read all positive updates
Company Guidance
During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.EKSO BIONICS Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.56M | 12.80M | 17.93M | 18.28M | 12.91M | 11.25M |
| Gross Profit | 6.11M | 6.84M | 9.51M | 9.08M | 6.21M | 6.75M |
| EBITDA | -13.35M | -9.81M | -9.45M | -13.20M | -14.04M | -9.09M |
| Net Income | -15.69M | -11.70M | -11.33M | -15.20M | -15.08M | -9.76M |
Balance Sheet | ||||||
| Total Assets | 19.67M | 20.11M | 26.65M | 28.92M | 40.90M | 49.17M |
| Cash, Cash Equivalents and Short-Term Investments | 3.99M | 1.17M | 6.49M | 8.64M | 20.52M | 40.41M |
| Total Debt | 4.32M | 2.64M | 5.98M | 7.17M | 7.50M | 2.22M |
| Total Liabilities | 13.93M | 11.08M | 13.95M | 16.31M | 15.46M | 11.95M |
| Stockholders Equity | 5.74M | 9.03M | 12.71M | 12.61M | 25.44M | 37.22M |
Cash Flow | ||||||
| Free Cash Flow | -11.96M | -11.99M | -9.88M | -12.21M | -14.88M | -11.21M |
| Operating Cash Flow | -11.96M | -11.80M | -9.85M | -12.05M | -14.69M | -11.16M |
| Investing Cash Flow | -178.00K | -188.00K | -37.00K | -157.00K | -5.17M | -59.00K |
| Financing Cash Flow | 8.05M | 6.63M | 7.77M | 348.00K | 0.00 | 38.71M |
EKSO BIONICS Technical Analysis
Positive
10.15
Price Trends
10.47
Positive
8.57
Positive
6.39
Positive
Market Momentum
-0.11
Negative
56.19
Neutral
90.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EKSO, the sentiment is Positive. The current price of 10.15 is above the 20-day moving average (MA) of 10.00, below the 50-day MA of 10.47, and above the 200-day MA of 6.39, indicating a bullish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 90.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EKSO.
EKSO BIONICS Risk Analysis
EKSO BIONICS disclosed 39 risk factors in its most recent earnings report. EKSO BIONICS reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
EKSO BIONICS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $28.53M | -0.52 | -388.56% | ― | -8.06% | -350.49% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $24.94M | -5.14 | -164.78% | ― | 3.99% | -17.45% | |
47 Neutral | $42.80M | -1.38 | -197.81% | ― | -34.08% | 26.18% | |
42 Neutral | $6.62M | -0.73 | -74.10% | ― | 62.65% | 68.99% |
* Healthcare Sector Average
EKSO
EKSO BIONICS
11.79
4.64
64.90%
HBIO
Harvard Bioscience
6.36
3.06
92.79%
MLSS
Milestone Scientific
0.34
-0.65
-65.69%
LUCY
Innovative Eyewear, Inc.
1.03
-0.87
-45.74%
EKSO BIONICS Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Ekso Bionics to Acquire Cloud Unit, Rebrand ChronoScale
Negative
Feb 17, 2026
On February 15, 2026, Ekso Bionics entered into a Contribution and Exchange Agreement with subsidiaries of Applied Digital Corporation to acquire all of Applied Digital Cloud Corporation in exchange for issuing 138,216,820 new Ekso shares, with cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.